deltatrials
Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04967833

A Study of GC101 TIL in Advanced Solid Tumors (TR)

A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Malignant Solid Tumors

Sponsor: Shanghai Juncell Therapeutics

Conditions Advanced Solid Tumors
Interventions Tumor Infiltrating Lymphocytes (TIL)
Updated 11 times since 2021 Last updated: Dec 4, 2025 Started: Apr 22, 2021 Primary completion: Dec 22, 2025 Completion: Apr 22, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Advanced Solid Tumors, this trial is actively recruiting participants. The trial is conducted by Shanghai Juncell Therapeutics and has accumulated 11 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshotRecruiting~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshotRecruiting~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshotRecruiting~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshotRecruiting~Jan 2023 – ~Oct 2023 · 9 months · monthly snapshotRecruiting~Oct 2023 – ~May 2024 · 7 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshotRecruiting~Nov 2025 – ~Jan 2026 · 2 months · monthly snapshotRecruiting~Jan 2026 – present · 7 months · monthly snapshotRecruiting

Change History

11 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting EARLY_PHASE1

  2. Nov 2025 — Jan 2026 [monthly]

    Recruiting EARLY_PHASE1

  3. Sep 2024 — Nov 2025 [monthly]

    Recruiting EARLY_PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

  5. May 2024 — Jul 2024 [monthly]

    Recruiting EARLY_PHASE1

▶ Show 6 earlier versions

  1. Oct 2023 — May 2024 [monthly]

    Recruiting EARLY_PHASE1

  2. Jan 2023 — Oct 2023 [monthly]

    Recruiting EARLY_PHASE1

  3. Sep 2022 — Jan 2023 [monthly]

    Recruiting EARLY_PHASE1

  4. Jul 2022 — Sep 2022 [monthly]

    Recruiting EARLY_PHASE1

  5. Dec 2021 — Jul 2022 [monthly]

    Recruiting EARLY_PHASE1

  6. Sep 2021 — Dec 2021 [monthly]

    Recruiting EARLY_PHASE1

    First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Juncell Therapeutics
  • Shanghai Tong Ren Hospital
Data source: Shanghai Juncell Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations